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Abstract
Background Diffuse large B-cell lymphoma (DLBCL) is
the commonest non-Hodgkin lymphoma. Previous studies
examining the cost of treating DLBCL have generally
focused on a specific first-line therapy alone; meaning that
their findings can neither be extrapolated to the general
patient population nor to other points along the treatment
pathway. Based on empirical data from a representative
population-based patient cohort, the objective of this study
was to develop a simulation model that could predict costs
and life expectancy of treating DLBCL.
Methods All patients newly diagnosed with DLBCL in
the UK’s population-based Haematological Malignancy
Research Network (www.hmrn.org) in 2007 were followed
until 2013 (n = 271). Mapped treatment pathways,
alongside cost information derived from the National Tariff
2013/14, were incorporated into a patient-level simulation
model in order to reflect the heterogeneities of patient
characteristics and treatment options. The NHS and social
services perspective was adopted, and all outcomes were
discounted at 3.5 % per annum.
Results Overall, the expected total medical costs were
£22,122 for those treated with curative intent, and £2930
for those managed palliatively. For curative chemotherapy,
the predicted medical costs were £14,966, £23,449 and
£7376 for first-, second- and third-line treatments, respec-
tively. The estimated annual cost for treating DLBCL
across the UK was around £88–92 million.
Conclusions This is the first cost modelling study using
empirical data to provide ‘real world’ evidence throughout
the DLBCL treatment pathway. Future application of the
model could include evaluation of new technologies/
treatments to support healthcare decision makers, espe-
cially in the era of personalised medicine.
Keywords Diffuse large B-cell lymphoma  DLBCL 
Cost  Discrete event simulation  Patient-level simulation
JEL Classification D24  D61  E17  H43  I11
Introduction
With an annual incidence of around 10.2 per 100,000 in
adults, diffuse large B-cell lymphoma (DLBCL) is the
commonest lymphoma subtype, accounting for around
40 % of the total [1, 2]. Although rapidly fatal if left
untreated, DLBCL is potentially curable [3]. Introduced in
the 1970s, chemotherapy with cyclophosphamide com-
bined with doxorubicin, vincristine and prednisone
(CHOP) [4] resulted in a response rate of around 60 %
and a long-term cure rate of 30 % [5, 6]; the addition of the
monoclonal antibody rituximab in the 1990s increased the
latter to 45 % [7].
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Hitherto, although several economic studies have been
carried out, the majority have focused on comparing the
cost-effectiveness of CHOP and R-CHOP (CHOP plus
rituximab) [8–17]. In addition, most of the relevant data
has come from trials that only include patients treated with
curative intent [9–12, 14, 16]; making findings difficult to
extrapolate to the general patient population.
The objective of this study was to develop an economic
model that could (1) model across the whole treatment
pathway, rather than being limited to first-line treatment or
a specific agent alone, (2) reflect real world practice rather
than the idealized predefined setting of a randomised
controlled trial, and (3) predict medical costs and life
expectancy. Such a predictive disease model is particularly
important for evaluating the cost-effectiveness of new
interventions and for allocating health resources efficiently.
To the best of our knowledge, no such model has been
previously developed for DLBCL.
Method
Data sources
The individual-level data used for constructing the simu-
lation model are from a specialist UK population-based
registry, the Haematological Malignancy Research Net-
work (www.hmrn.org); the methods of which have been
previously described [1, 18]. Briefly, since September
2004, all patients newly diagnosed with a haematological
malignancy (leukaemias, lymphomas, and myelomas) in a
catchment population of more than 3.6 million have been
routinely ascertained and followed-up. HMRN has
Sect. 251 support under the NHS Act 2006, which allows
all patients regardless of consent, to have full-treatment,
response and outcome data collected to clinical trial stan-
dards; and to be ‘flagged’ for death and subsequent cancer
registrations at the national Medical Research Information
Service (MRIS) and linked to nationwide information on
Hospital Episode Statistics (HES).
The current study includes all adult patients (C18 years)
newly diagnosed with de novo DLBCL (International
Classification of Disease for Oncology, 3rd edition: 9680/3,
9735/3, 9712/3, and 9679/3) within HMRN in 2007
(N = 271). All patients were followed for 5 years from the
date of diagnosis, and treatment pathways were individu-
ally mapped out according to the chemotherapy regimens
received. A more detailed summary of patient character-
istics is presented in Supplementary Table 1.
Model structure
In order to reflect the current treatment strategies, while
also being responsive to future changes, a discrete event
based micro-simulation model was constructed using
Simul8 software (Simul8 2013 Professional version,
Simul8 Corporation, Boston, MA, USA). The model first
assigned attributes (such as age at diagnosis, sex and
prognostic factors) to a group of simulated patients, and
then moved each patient forward to the next event, based
both on their characteristics and on the timing of the events
instead of fixed time cycles.
The model structure was based on patient treatment
pathways determined from empirical HMRN data, expert
opinion and clinical guidelines. The structure of the model
is shown in Fig. 1, and a simplified version of the model
can be found via the following link https://www.hmrn.org/
economics/models. Date of diagnosis defines the start of
the model; with costs for diagnostic tests such as biopsies,
scans, electrocardiography (ECG) and echocardiography
(ECHO) being included. After diagnosis, the model splits
into two branches according to whether the initial decision
was to administer first-line chemotherapy with curative
intent or manage supportively using a palliative approach.
This is a unique and important feature of the model,
ensuring the results reflect ‘real world’ practice and capture
the fact that some patients are managed palliatively from
the date of diagnosis until death. For those who entered the
first-line curative treatment branch, different chemotherapy
regimens, with or without supportive care, were assigned to
each patient. The probability of receiving each treatment
varied according to the patient’s individual attributes [such
as age, disease stage and central nervous system (CNS)
involvement]. This design allowed the model to capture the
differences in ‘cost’ and ‘time in treatment’ between
alternative regimens. However, it was beyond the scope of
this study to compare the economic impact of different
first-line chemotherapies.
Once first-line treatment had been received, one of three
outcomes was assigned to each individual: died during
treatment, responded to treatment, and no response to
treatment. The probabilities of these outcomes were
dependent on the first-line chemotherapy regimen and age
at diagnosis.
For individuals who responded to first-line treatment,
one of three events could occur: relapse, remain in remis-
sion until cured (defined as staying in remission C5 years)
and death in remission. For those who were deemed to be
cured, it was assumed that mortality returned to that of the
H.-I. Wang et al.
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general population and no subsequent DLBCL-related
medical costs were incurred.
For individuals who relapsed or had disease that was
refractory to treatment, two further options were possible:
further potentially curative treatment or the adoption of an
end-of-life (palliative) approach. The probability of the
decision was dependent on age at diagnosis, previous
chemotherapy regimen and response. For those who were
not treated curatively, end-of-life care included all care
given from last chemotherapy until death. For those who
received second-line treatment, different types of
chemotherapy regimens with or without autologous stem-
cell transplant (ASCT) were included. Following this, each
patient could remain in remission, receive third-line treat-
ment, or receive end-of-life care; with the decision process
being identical to that for first-line treatment. Few patients
received treatment post third-line; so for the purposes of
the model it was assumed that those who did had similar
treatment patterns and response rates to those observed at
third line.
The key input parameters used in the model are listed in
Tables 1. For more details, please refer to Supplementary
Tables 2–4.
Model inputs: medical costs
The model was built from an NHS perspective; and only
medical costs directly related to DLBCL management were
considered. This included costs for diagnosis, treatment,
supportive care, follow-up and end-of-life care. Details of
the cost items and different chemotherapy regimens
included in each costing phase can be found in Supple-
mentary Table 5.
All cost parameters were calculated using the National
Tariff 2013/14 [19], representing the reimbursement/ex-
penditure of NHS for treating the DLBCL population. For
costs that were locally negotiated, such as the costs of
chemotherapy regimens, information was derived from the
Leeds Teaching Hospital NHS Trust. The inflated NHS
reference cost 2012/13 [20] was used only when data were
not available. All costs were expressed in 2013 British
pound sterling; and the detailed cost information (unit
costs) used in the model is summarised in Table 2.
Model inputs: time to event
Time-to-event (TTE) is a key element for discrete event
simulation. Several time-to-event analyses were carried out
using empirical data derived from HMRN to estimate the
distributions associated with time between two events. This
included the time from diagnosis to treatment, time in
treatment, time from response to relapse, time from
response to death and time in end-of-life care. All time-to-
event analyses (survival analyses) were based on the best fit
distributions as a function of patient’s age, treatment intent
and treatment details. Five parametric survival models
(exponential, Weibull, log-normal, log-logistic and Gom-
pertz distributions) were tested and the best fit model was
determined using the Akaike information criterion (AIC)
score. It was assumed that cured patients’ mortality would
return to normal, and the distribution of time to death was
generated using the United Kingdom National Life Table,
2011–2013 [21]. The key parameters used in the model are
illustrated in Fig. 2a–d. For more details on the time-to-
event analyses, please refer to Supplementary Table 6.
Model outputs
Health outcome was measured by life-years gained (LYG),
while economic outcomes were captured by medical costs.
Both economic and health outcomes were discounted using
a 3.5 % annual discount rate, based on UK guidance rec-
ommended by the National Institute for Health and Clinical
Excellence (NICE) [22].
Fig. 1 Model structure
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Table 1 Key model parameters
Parameters Estimates Distribution
Patient generation state
Age (years) Empirical Beta Mean (sd): 67.8 (14.7)
Beta (3.73, 2.32)
Sex
Age B40 Male: 0.56 Beta a = 9, b = 7
Age 40–50 Male: 0.68 Beta a = 15, b = 7
Age 50–60 Male: 0.71 Beta a = 29, b = 12
Age 60–70 Male: 0.50 Beta a = 31, b = 31
Age 70–80 Male: 0.55 Beta a = 42, b = 35
Age C80 Male: 0.51 Beta a = 27, b = 26
Diagnosis
Diagnostic test results
Age B40 Stage IA: 0.06 Dirichlet a1 = 2
CNS involvement: 0.0 a2 = 1
Standard: 0.94 a3 = 16
Died before diagnosis: 0.0 a4 = 2
Age 40–50 Stage IA: 0.09 Dirichlet a1 = 3
CNS involvement: 0.09 a2 = 3
Standard: 0.77 a3 = 18
Died before diagnosis: 0.05 a4 = 2
Age 50–60 Stage IA: 0.15 Dirichlet a1 = 7
CNS involvement: 0.08 a2 = 4
Standard: 0.75 a3 = 32
Died before diagnosis: 0.02 a4 = 2
Age 60–70 Stage IA: 0.06 Dirichlet a1 = 5
CNS involvement: 0.02 a2 = 2
Standard: 0.90 a3 = 57
Died before diagnosis: 0.02 a4 = 2
Age 70–80 Stage IA: 0.12 Dirichlet a1 = 10
CNS involvement: 0.01 a2 = 2
Standard: 0.75 a3 = 59
Died before diagnosis: 0.12 a4 = 10
Age C80 Stage IA: 0.05 a1 = 4
CNS involvement: 0.00 a2 = 1
Standard: 0.89 a3 = 48
Died before diagnosis: 0.06 a4 = 4
Initial treatment decision
Age B40 Treated: 0.94 Beta a = 15, b = 1
Age 40–50 Treated: 0.95 Beta a = 21, b = 1
Age 50–60 Treated: 0.96 Beta a = 39, b = 2
Age 60–70 Treated: 0.88 Beta a = 55, b = 7
Age 70–80 Treated: 0.75 Beta a = 58, b = 19
Age C80 Treated: 0.54 Beta a = 29, b = 24
Treatment decision for patients refractory to first-line chemotherapy
Age B60 Treated: 0.86 Beta a = 6, b = 1
Age 60–80 Treated: 0.33 Beta a = 4, b = 8
Age C80 Treated: 0.00 Beta a = 0, b = 6
H.-I. Wang et al.
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Assessing uncertainty
Probabilistic sensitivity analysis was performed on all
parameters in order to explore the cumulative uncertainty of
the model. Each parameter was assigned a distribution to
reflect sample variability, whilst coefficients of survival
models were assigned multivariate normal distributions.
Then, Monte Carlo simulations were carried out by sampling
parameters from the corresponding distributions simultane-
ously over a large number of iterations until stable results
were reached (500 times). All outputs from the iterations
were summarised with 95 % confidence intervals [23].
Analysis
To investigate the impact on the UK as a whole, the annual
number of expected cases in the UK (N = 4880) derived
from HMRN rates was used to run the simulation model
www.hmrn.org/statistics/incidence. Incidence-based results
were presented in aggregate, as well as for the time hori-
zons of 5-year, 15-year, and lifetime (simulated until
100 years of age or death). Survival beyond 5 years
was extrapolated based on the best fit time-to-event
distributions derived from the empirical data and the UK
National Life Table, 2011–2013 [21]. See ‘‘Model inputs:
time to event’’ in Methods for details.
To further investigate the effect of age, a sub-simulation
was conducted to capture differences in cost and life-years
gained for two age groups: under 70 and over 70 years of
age. In addition, using the expected number of new cases of
DLBCL diagnosed each year in the UK (N = 4880), the
model further simulated national prevalence-based costs
and life-years gained. Results were collected after a burn-
in period of 10 years.
Validation
The model was validated by means of standard methods,
including face, internal and external validations [24]. Face
validation was conducted while the model was under
construction by consulting clinical experts on model
structure, data sources and results. Internal validation was
assessed by comparing predicted costs and life-years
gained with empirical estimates, and external validation
was carried out by comparing simulated results with rele-
vant literature.
Table 1 continued
Parameters Estimates Distribution
Treatment decision for patients relapsed following first-line chemotherapy
Age B60 Treated: 0.93 Beta a = 14, b = 1
Age 60–80 Treated: 0.53 Beta a = 8, b = 7
Age C80 Treated: 1.00 Beta a = 2, b = 0
Treatment decision for patients refractory to second-line chemotherapy
Age B60 Treated: 0.50 Beta a = 4, b = 4
Age 60–80 Treated: 0.50 Beta a = 3, b = 3
Age C80 Treated: 0.00 Beta a = 0, b = 1
Treatment decision for patients relapsed following second-line chemotherapy
Age B60 Treated: 0.50 Beta a = 1, b = 1
Age 60–80 Treated: 0.00 Beta a = 0, b = 1
Age C80 Treated: 0.00 Beta a = 0, b = 1
Treatment decision for patients refractory to third-line chemotherapy
Age B60 Treated: 0.50 Beta a = 0, b = 3
Age 60–80 Treated: 0.00 Beta a = 0, b = 1
Age C80 Treated: 0.00a Beta a = 0, b = 1
Treatment decision for patients relapsed following third-line chemotherapy
Age B60 Treated: 0.50a Beta a = 1, b = 1
Age 60–80 Treated: 0.00a Beta a = 0, b = 1
Age C80 Treated: 0.00a Beta a = 0, b = 1
CNS central nervous system
a The probability was assumed to be the same as the probability in the second line due to lack of data
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Results
Incidence-based results
Predicted costs, as well as life-days gained over 5-year,
15-year, and lifetime horizons are presented in Table 3
according to the simulation results of the model. Results
for the 5-year horizon provide meaningful clinical esti-
mates and allow internal validation, and results for the
lifetime horizon provide insight into the overall economic
and health impacts throughout the treatment pathway.
Results over a 15-year time horizon are presented for the
Table 2 Summary of key unit
costs
Unit cost Source
Inpatient stay
Spell cost £797 National Tariff 2013/14
Cost per excess bed day £243 National Tariff 2013/14
Outpatient visit
First attendance (single profession) £247 National Tariff 2013/14
First attendance (multi-profession) £248 National Tariff 2013/14
Follow-up visit (single profession) £113 National Tariff 2013/14
Follow-up visit (multi-profession) £174 National Tariff 2013/14
Diagnostic procedures
Diagnostic biopsy £260 National Tariff 2013/14a
Staging biopsyb £503 National Tariff 2013/14
Imaging
Computed tomography (CT) £105 National Tariff 2013/14
Magnetic resonance imaging (MRI) £206 National Tariff 2013/14
Positron emission tomography (PET) £748 National Tariff 2013/14
Ultrasound £51 National Tariff 2013/14
Electrocardiography (ECG) £172 National Tariff 2013/14
Echocardiography (Echo) £322 National Tariff 2013/14
Radiotherapy
Planning £769 National Tariff 2013/14
Per fraction £123 National Tariff 2013/14
Chemotherapy (per cycle)
CHOP £289 Leeds Teaching Hospitals Trust
R-CHOP £1730 Leeds Teaching Hospitals Trust
R-CVP £1486 Leeds Teaching Hospitals Trust
CODOX-M/IVAC-R £6241 Leeds Teaching Hospitals Trust
IDARAM £2006 Leeds Teaching Hospitals Trust
R-DHAP £1952 Leeds Teaching Hospitals Trust
R-ESHAP £3344 Leeds Teaching Hospitals Trust
MiniBEAM £446 Leeds Teaching Hospitals Trust
Methotrexate (low dose intrathecal) £5 Leeds Teaching Hospitals Trust
Methotrexate (high dose) £861 Leeds Teaching Hospitals Trust
Autologous stem-cell transplant (ASCT) £42,000 Leeds Teaching Hospitals Trust
CHOP cyclophosphamide, doxorubicin, vincristine and prednisone, R-CHOP cyclophosphamide, dox-
orubicin, vincristine, prednisone and rituximab, R-CVP cyclophosphamide, vincristine, prednisone and
rituximab, CODOX-M/IVAC-R cyclophosphamide, doxorubicin, vincristine, methotrexate/ifosfamide,
etoposide, high dose cytarabine and rituximab, IDARAM rituximab, idarubicin, dexamethasone, cytarabine
and methotrexate, R-DHAP dexamethasone, cytarabine, cisplatin and rituximab, R-ESHAP etoposide,
methylprednisolone, cytarabine, cisplatin and rituximab, MiniBEAM carmustine, etoposide, cytarabine and
melphalan
a Average of National Tariffs 2013/14
b Including: BMAT bone marrow aspirate and trephine, BMA bone marrow aspirate and TB bone marrow
trephine
H.-I. Wang et al.
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purpose of external comparison, as most published esti-
mates are for this time period.
Overall, the average cost per patient was around
£18,000. This figure is consistent regardless of the time
horizon chosen (£18,096, £18,396 and £18,396 for 5-year,
15-year and lifetime, respectively). This reflects the fact
that for most DLBCL patients, treatment is completed
within the 5-year time frame. However, the predicted life-
years gained varied with time horizon: being 2.8, 6.3 and
10.0 for 5-year, 15-year and lifetime, respectively.
As expected, the costs for patients who received treat-
ment with curative intent were significantly higher
(£22,122), with more life-years gained (12.6 LYG) than for
patients who were not treated (£2930, 0.1 LYG). This also
applied to patients who received treatment post second-
line. For patients who received ASCT as second-line
treatment, costs were higher, but longer survival was
observed (19.9 LYG and 7.6 LYG for ASCT and non-
ASCT at second-line, respectively).
Table 4 shows the cost and time-to-next-event compo-
nents of the overall treatment pathway over the lifetime
horizon. As shown, treatment cost is the main component
of the total costs. This is particularly prominent for second-
line treatment involving ASCT (£56,442). For end-of-life
care, patients who were not treated incurred less costs
(£2930) than those who were treated prior to receiving end-
of-life care (£4767).
Sub-group analysis
Figure 3 shows the effect of age for subgroups with dif-
ferent initial treatment intents. As expected, patients
younger than 70 years had better survival but incurred
more medical costs than those aged 70 years or more.
Fig. 2 Time to event analyses. a Time in treatment. b Time in first response to either death or relapse. c Time in second response to either death
or relapse. d Time in end-of-life care
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However, for those who did not receive treatment with
curative intent, medical costs and survival were similar
between the two age groups.
Figure 3 also demonstrates the effect of time-horizon
choice. As shown in Fig. 3b and e, among treated patients,
survival differed between the two age groups (6255 and
2080 days over the lifetime). However, over a 5-year time
horizon, the differences in life-years gained and costs were
much smaller (1408 vs 1065 days); confirming that patients
who were over the age of 70 responded as well as those
who were younger.
Prevalence-based results
The prevalence-based cost demonstrates the total cost
associated with treating existing and new DLBCL patients
during a 1-year period. The results are summarised in
Fig. 4. As shown, the total annual costs for treating the
DLBCL patient population across the UK as a whole was
in the region of £88 million for the lower bound and £92
million for the upper bound.
Model validation
With respect to face validity, the model structure, data
source, and results were corroborated by consultant
haematologists (CB and RP). For internal validity, the
simulated/predicted outcomes were compared to empirical
estimates derived from HMRN. The survival curves over a
5-year period are compared in Fig. 5. As shown, the sim-
ulated results closely match the 5-year follow-up empirical
data, demonstrating good fit with empirical evidence. With
regard to medical costs, the average 5-year simulated cost
was £18,096 per patient (ranging from £18,078 to £18,114
among 500 iterations), capturing 98 % of the empirical
results derived from the study population (£18,515).
Regarding external validity, the simulated cost and
survival results were broadly similar to the findings in
earlier literature [8, 10, 16, 17]. Taking the average costs of
first-line treatment with R-CHOP as an example: for those
over 60 years of age, our 5-year result of £20,831 is close
to the US estimate of £19,485 [16] and the UK estimate of
£19,805 [10], but less than the Canadian estimate of
£26,498 [8]. For those under 60 years of age, our 15-year
result of £26,761 is close to the Canadian estimate of
£28,626 [8], but more than the UK estimate of £20,798 [10]
(all currencies were inflated and converted to 2013 British
pound sterling). Regarding the average survival time fol-
lowing R-CHOP, for those over 60 years of age, our
15-year result of 7.87 years is close to the estimate of
6.2 years from Johnston’s study [8] and the estimate of
6.23 years from Knight’s study [10]. For those under
60 years of age, our 15-year result of 11.8 years is slightlyT
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more than Knight’s estimate of 9.9 years [10] and John-
ston’s estimate of 8.3 years [8]. Thus, overall, our model
demonstrated good capability for predicting both medical
costs and life expectancy. For more details, please refer to
online Supplementary Table 7.
Discussion
This is the first DLBCL model to simulate and predict
treatment costs and life-years gained throughout the treat-
ment pathway. Whilst several economic models have pre-
viously been constructed and published for DLBCL, all
were built for the purpose of assessing the cost-effective-
ness of adding rituximab to CHOP, not for overall disease
treatments [8–10, 14–16]. Hence, although these reports
confirmed the fact that adding rituximab to CHOP was
cost-effective, none could examine the overall economic
impact to health insurers or policy makers. In addition, this
is the first DLBCL model to incorporate data on patients
who were not treated with curative intent; enabling the
production of more accurate estimates of the economic
impact of DLBCL among different patient groups, as well
as across the patient population as a whole. This flexibility
allowed quantities such as the prevalence-based economic
impact at a national level to be explored for the first time.
In the current study, a discrete event simulation (DES)
model was built for analysis. The DES model generated
individual treatment histories within the set time horizon
for hypothetical DLBCL patients based on ‘real-world’
observational data. Estimates for the 5-year expected
medical cost and life-years gained were £18,096 and
2.8 years, respectively, while the lifetime expected medical
cost and survival were £18,396 and 10.0 years, respec-
tively. Curative treatment results in a high number of life-
years gained at the relatively moderate cost of £1535 per
life-year gained (95 % CI £1534–£1537 per life-year
gained) compared to non-curative care only. The variabil-
ity was driven largely by initial treatment, age at diagnosis,
and whether the patient had an ASCT. The expected life-
time medical cost ranged from £79,131 to £2930, while the
life expectancy ranged from 30 days to 19 years (Table 3).
With respect to appropriate time horizons, this study
demonstrated that the differences in estimated costs
derived from 5-year, 15-year, and lifetime horizons were
relatively minor, reflecting the high response rate amongst
treated patients. However, the differences in estimated life-
years gained were considerable (Table 3); confirming, as
has been suggested by others [14], that the lifetime horizon
is the optimal approach as it allows the overall effects of
treatment to be fully captured. Furthermore, as expected,
patients younger than 70 years had better survival and
therefore incurred higher medical costs (Fig. 3). Impor-
tantly, however, in the 5-year time frame the differences in
costs and life-years gained between these two age groups
were small, demonstrating that patients over 70 years who
receive chemotherapy responded as well as their younger
counterparts. In this context, it is important to note that
a patient’s performance status has been shown to be more
discriminatory of survival than chronological age [25].
Finally, although the average cost of treating DLBCL is
considered moderate in comparison to some other cancers
(£18,396, see Table 1), the annual economic impact of
treating existing and new DLBCL patients in the UK is
considerable (in the region of £88–£92 million, see Fig. 4);
accounting for approximately 1/6th of the annual UK NHS
Table 4 Costs and time-to-
event breakdowns for treated
DLBCL patients (based on life-
time horizon)
N Cost (£) Duration of event (days)
Mean (95 % CI) Mean (95 % CI)
Diagnosis 4880 1326 (1325–1327) –
Treatment
First-line treatment 3892 14,966 (14,958–15,974) 122 (121–123)
Second-line treatment 577 23,449 (23,365–23,534) 81 (80–82)
With ASCT 167 56,442 (56,409–56,474) 104 (103–105)
Without ASCT 409 9956 (9932–9981) 72 (71–73)
Third-line treatment 106 7376 (7374–7406) 50 (49–51)
Follow-up
During first response 3001 1401 (1400–1402) 5125 (5117–5132)
During second
response
296 1371 (1369–1374) 6135 (6106–6163)
End-of-life care
For not treated patients 988 2930 (2918–2942) 30 (29–31)
For treated patients 704 4767 (4755–4780) 60 (60–61)
ASCT autologous stem-cell transplant
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budget for haematological diseases as a whole [26] and
providing around 35,000 life-years gained per year (data
not shown).
Predicated on ‘real-world’ data, this model produced
findings that can be extrapolated to the general patient
population; which is not the case for models built using
data from clinical trials [9–12, 14, 16]. The reliability and
robustness of the model are also confirmed by the internal
and external validations. For internal validation, the sim-
ulated cost and life-year results were close to the empirical
Five-year time horizon
(based on 500 model runs)
Life time horizon
(based on 500 model runs)
(a)
(b)
(c)
(d)
(e)
(f)
N Mean cost (£) Mean survival 
(days)
N Mean cost Mean 5-year 
survival (days)
≤70 years
Overall 2541 22,665 (22,637-22,693) 5,761 (5,751-5,770) 2541 22,162 (22,135-22,190) 1,299 (1,298-1,300)
Treated 2340 24,306 (24,276-24,335) 6,255 (6,245-6,265) 2340 23,759 (23,730-23,788) 1,408 (1,407-1,410)
Not Treated 202 3,632 (3,604-3,659) 30 (29-31) 202 3,632 (3,604-3,659) 30 (29-31)
>70 years
Overall 2339 13,757 (13,736-13,778) 1,391 (1,387-1,395) 2339 13,622 (13,601-13,643) 717 (716-719)
Treated 1553 18,830 (18,806-18,854) 2,080 (2,075-2,085) 1553 18,627 (18,603-18,650) 1,065 (1,064-1,067)
Not Treated 786 3,734 (3,720-3,748) 30 (30-31) 786 3,734 (3,720-3,748) 30 (30-31)
Fig. 3 Simulated cost and survival between two age groups for three
groups: a Overall. b Patients who received initial treatments and
c patients who did not receive initial treatment over lifetime horizon,
and d overall. e Patients who received initial treatments and f patients
who did not receive initial treatment over 5-year time horizon
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HMRN data (Fig. 5). For external validation, the model
results were in line with the findings from other observa-
tional studies: the micro-costing study conducted in
Canada [17] and the Medicare claims study conducted in
the US [16]. Moreover, the structure of our DES model
provided an opportunity to make detailed comparisons with
findings from more restricted datasets: and when the
parameters (e.g. specific age groups, chemotherapy regi-
mens and time horizons) from those studies were applied to
the model, the results were found to be in line with most of
the relevant studies [8, 10, 16, 17] (please refer to ‘‘Model
validation’’).
The molecular heterogeneity of DLBCL coupled with
recent advances in diagnostic technologies [27, 28] is
resulting in the development of more targeted approaches
to the treatment of this complex cancer. The recent UK
Phase 3 trial (REMoDL-B), for example, used gene
expression profiling to assign DLBCL patients to different
treatment arms [29]; and, as science continues to advance
and new treatments emerge, reliable models such as the
one developed here will become increasingly important in
this rapidly changing field. Furthermore, the reduced side-
effects and toxicities of many of these novel therapeutic
agents mean that the proportion of the patient population
who receive treatment will continue to increase. Accord-
ingly, our model’s ability to accurately predict the impact
of these changes across the entire population of patients
with DLBCL will not only support commissioners to
allocate resources, but will also aid clinical decision
making.
With respect to model limitations, the current study did
not deal with an administrative censoring effect. However,
this is unlikely to impact on results, as the degree of
administrative censoring is non-informative (independent
of treatment). Also, the model is validated by the results
which are broadly similar to the findings in earlier litera-
ture. In addition, whilst cost inputs were mainly confined to
inpatient and day-case settings, the majority of costs will
have been captured since around 85 % of cancer spending
is incurred in acute/secondary care settings [26]. Moreover,
as the model is based on an empirical follow-up time of
only 5 years, the results for treated patients need to be
interpreted with caution. Nonetheless, as the majority of
treatments are carried out within the first 5 years, the costs
estimates will be largely unaffected (see Table 3). It is,
however, worth noting that our long-term estimates are
conservative since they do not include health care costs for
comorbidities that could potentially have been caused by
DLBCL therapy. Quality adjusted life years (QALY) were
not used in the model, as this information was not available
for this cohort of patients and currently no other high
quality QALY information is published in the existing
literature, an issue recognised by other researchers [10, 15].
Fig. 4 Annual cost
(prevalence-based cost) for
treating DLBCL population
across the UK as a whole
Fig. 5 Survival curves of empirical and probabilistic models
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However, the model has been built to allow QALY data to
be incorporated in the future and we are now collecting
European Quality of Life-5 Dimensions (EQ-5D) infor-
mation from patient cohort members.
Conclusion
Life expectancy and costs of treating DLBCL patients vary
according to patient characteristics and treatment path-
ways. However, the population-based model developed in
the current study demonstrated a good capability of cap-
turing the medical costs to healthcare commissioners, as
well as the life-years gained in a real world setting.
Importantly, the model produces different outputs for dif-
ferent purposes; estimating total costs along with health
benefits at varying time points for specific patient cohorts,
as well as generating prevalence-based costs for all patients
over specific time periods. Future application of the model
could include evaluation of new technologies/treatments to
support healthcare decision makers, especially in the era of
personalised medicine.
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